Literature DB >> 30312208

Predictors of Survival for Patients with Acute Decompensated Heart Failure Requiring Extra-Corporeal Membrane Oxygenation Therapy.

A Reshad Garan1, Waqas A Malick1, Marlena Habal1, Veli K Topkara1, Justin Fried1, Amirali Masoumi1, Aws K Hasan1, Dimitri Karmpaliotis1, Ajay Kirtane1, Melana Yuzefpolskaya1, Maryjane Farr1, Yoshifumi Naka2, Dan Burkhoff1, Paolo C Colombo1, Paul Kurlansky2, Hiroo Takayama2, Koji Takeda2.   

Abstract

Chronic systolic heart failure (HF) with acute decompensation can result in cardiogenic shock (CS) requiring short-term mechanical circulatory support. We sought to identify predictors of survival for acute decompensated HF (ADHF) patients requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Patients >18 years old treated at our institution with VA-ECMO from 2009 to 2018 for ADHF with CS were studied. Demographic, hemodynamic, and echocardiographic data were collected. The primary outcome was survival to discharge. Fifty-two patients received VA-ECMO for ADHF with CS; 24 (46.2%) survived. Seventeen (32.7%) had suffered cardiac arrest, and 37 (71.2%) were mechanically ventilated. Mean lactate was 4.33 ± 3.45 mmol/L, and patients were receiving 2.7 ± 1.2 vasopressor/inotropic infusions at ECMO initiation; these did not differ significantly between survivors and nonsurvivors. Pre-ECMO cardiac index was 1.84 ± 0.56L/min/m and 1.94 ± 0.63L/min/m in survivors and nonsurvivors, respectively (p = 0.57). In multivariable analysis, only diabetes mellitus (DM; OR, 13.25; CI, 1.42-123.40; p = 0.02) and mineralocorticoid receptor antagonist use (OR, 0.12; CI, 0.02-0.78; p = 0.03) were independent predictors of mortality. Nineteen (79.2%) survivors required durable ventricular assist device. Among ADHF patients receiving VA-ECMO, DM is a powerful predictor of outcomes while markers of clinical acuity including hemodynamics, vasopressor/inotrope use, and lactate are not. The vast majority of survivors required durable left-ventricular assist devices.

Entities:  

Mesh:

Year:  2019        PMID: 30312208      PMCID: PMC6456436          DOI: 10.1097/MAT.0000000000000898

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  24 in total

1.  Long-term use of a left ventricular assist device for end-stage heart failure.

Authors:  E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  Important role of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock.

Authors:  Lauren Truby; Yoshifumi Naka; Bindu Kalesan; Takeyoshi Ota; Ajay J Kirtane; Susheel Kodali; Natasha Nikic; Lily Mundy; Paolo Colombo; Ulrich P Jorde; Hiroo Takayama
Journal:  Eur J Cardiothorac Surg       Date:  2014-12-04       Impact factor: 4.191

3.  Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score.

Authors:  Matthieu Schmidt; Aidan Burrell; Lloyd Roberts; Michael Bailey; Jayne Sheldrake; Peter T Rycus; Carol Hodgson; Carlos Scheinkestel; D Jamie Cooper; Ravi R Thiagarajan; Daniel Brodie; Vincent Pellegrino; David Pilcher
Journal:  Eur Heart J       Date:  2015-06-01       Impact factor: 29.983

4.  Major advantages and critical challenge for the proposed United States heart allocation system.

Authors:  Lynne Warner Stevenson; Robert L Kormos; James B Young; James K Kirklin; Sharon A Hunt
Journal:  J Heart Lung Transplant       Date:  2016-04-16       Impact factor: 10.247

5.  National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis.

Authors:  Robert Stretch; Christopher M Sauer; David D Yuh; Pramod Bonde
Journal:  J Am Coll Cardiol       Date:  2014-10-07       Impact factor: 24.094

6.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

7.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

8.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

9.  Decade-Long Trends (2001-2011) in the Incidence and Hospital Death Rates Associated with the In-Hospital Development of Cardiogenic Shock after Acute Myocardial Infarction.

Authors:  Robert J Goldberg; Raghavendra Charan P Makam; Jorge Yarzebski; David D McManus; Darleen Lessard; Joel M Gore
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-02-16

10.  The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock.

Authors:  Grégoire Muller; Erwan Flecher; Guillaume Lebreton; Charles-Edouard Luyt; Jean-Louis Trouillet; Nicolas Bréchot; Matthieu Schmidt; Ciro Mastroianni; Jean Chastre; Pascal Leprince; Amedeo Anselmi; Alain Combes
Journal:  Intensive Care Med       Date:  2016-01-29       Impact factor: 17.440

View more
  7 in total

1.  Comparison of the Hemodynamic Response to Intra-Aortic Balloon Counterpulsation in Patients With Cardiogenic Shock Resulting from Acute Myocardial Infarction Versus Acute Decompensated Heart Failure.

Authors:  Waqas Malick; Justin Allan Fried; Amirali Masoumi; Abhinav Nair; Amelia Zuver; Athena Huang; Jennifer Haythe; Maryjane Farr; LeRoy Rabbani; Dimitri Karmpaliotis; Ajay Jayant Kirtane; Veli Kemal Topkara; Koji Takeda; Arthur Reshad Garan
Journal:  Am J Cardiol       Date:  2019-09-26       Impact factor: 2.778

2.  Contemporary Use of Venoarterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter RESCUE Registry.

Authors:  Rahul S Loungani; Marat Fudim; Dave Ranney; Ajar Kochar; Marc D Samsky; Desiree Bonadonna; Akinobu Itoh; Hiroo Takayama; Koji Takeda; Daniel Wojdyla; Adam D DeVore; Mani Daneshmand
Journal:  J Card Fail       Date:  2021-01-13       Impact factor: 5.712

3.  Recovery With Temporary Mechanical Circulatory Support While Waitlisted for Heart Transplantation.

Authors:  Veli K Topkara; Gabriel T Sayer; Kevin J Clerkin; Omar Wever-Pinzon; Koji Takeda; Hiroo Takayama; Craig H Selzman; Yoshifumi Naka; Daniel Burkhoff; Josef Stehlik; Maryjane A Farr; James C Fang; Nir Uriel; Stavros G Drakos
Journal:  J Am Coll Cardiol       Date:  2022-03-08       Impact factor: 24.094

4.  Outcomes of temporary mechanical circulatory support in cardiogenic shock due to end-stage heart failure.

Authors:  Hoong Sern Lim; Aaron Ranasinghe; David Quinn; Colin Chue; Jorge Mascaro
Journal:  J Intensive Care Soc       Date:  2021-01-22

Review 5.  ECMO in cardiogenic shock and bridge to heart transplant.

Authors:  Mathew Jose Chakaramakkil; Cumaraswamy Sivathasan
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-02-11

6.  Prospective Comparison of a Percutaneous Ventricular Assist Device and Venoarterial Extracorporeal Membrane Oxygenation for Patients With Cardiogenic Shock Following Acute Myocardial Infarction.

Authors:  A Reshad Garan; Koji Takeda; Michael Salna; John Vandenberge; Darshan Doshi; Dimitri Karmpaliotis; Ajay J Kirtane; Hiroo Takayama; Paul Kurlansky
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

7.  How I approach weaning from venoarterial ECMO.

Authors:  Justin A Fried; Amirali Masoumi; Koji Takeda; Daniel Brodie
Journal:  Crit Care       Date:  2020-06-08       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.